Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to enhance the PKPlus™ software.
“Following a rigorous evaluation of multiple commercial offerings, our partner selected PKPlus as the pharmacokinetics/toxicokinetics (PK/TK) modeling program to support the internal data platform that connects their global teams,” said Joshua Fohey, director of Operations for Simulations Plus. “Our interactions to date have been fantastic, and we look forward to collaboratively designing the next-generation engine that automates the import and mapping of data, selection of calculation templates, and generation of reports within a streamlined, validated system.”
John DiBella, Lancaster division president for Simulations Plus, added: “We have seen increasing adoption of PKPlus for several years and expect this to be accelerated as the functionality added through our collaboration is incorporated into versions that all companies and regulatory agencies can access, starting in 2020. We welcome this interaction and invite future collaborations to drive advances to modeling and simulation sciences.”